GlassScriptPhysician profile
Parven Khanna
NPI 1558346106
$2,028.80
in general payments reported to CMS, 2019-2025
22 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $138 · 2021: $50.20 · 2022: $162 · 2023: $325 · 2024: $358 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.32 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $270.52 | 2022-2024 | Quviviq |
| Amgen INC. | $237.94 | 2019-2022 | |
| Zyla Life Sciences, INC. | $221.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.71 | 2019-2025 | Relistor |
| Daiichi Sankyo INC. | $139.57 | 2019 | |
| Imperative Care, INC | $109.24 | 2024 | Prodigy Catheter |
| Pacira Therapeutics, INC. | $100.60 | 2019 | |
| Stimwave Technologies Incorporated | $95.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.09 | 2024 | Camzyos |
| Collegium Pharmaceutical, INC. | $53.23 | 2019-2021 | |
| Boston Scientific Corporation | $43.74 | 2020 | |
| Globus Medical, INC. | $42.95 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $42.54 | 2019 | |
| Tersera Therapeutics LLC | $32.20 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $29.11 | 2025 | Givlaari |
| Braeburn INC. | $21.91 | 2023 | Brixadi |
| Gilead Sciences, INC. | $19.86 | 2025 | |
| Shionogi INC | $19.79 | 2019 | |
| Pfizer INC. | $13.94 | 2019 | |
| Assertio Therapeutics, INC. | $13.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,519.86 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parven Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.